The results of this study showed that the expression of PTPRM in EOC was significantly different in patients varying in terms of age, clinical stage, the maximum diameter of the mass, and tumor recurrence in the subgroup; however,the differences were not significant in patients varying in the factors of pathological type, age of menarche, age of menostasis,number of pregnancies, family history, presence of medical comorbidities, tumor markers, presence of ascites, unilateral or bilateral masses, and presence of lymph node metastasis (Table 2, Fig. 3). This evidence concerns the gene PTPRM and metastatic malignant neoplasm in the lymph nodes.